Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK to suppress both B-cell activation and B-cell-mediated signaling, and is approved for the treatment of B cell cancers, including mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstr?m's Macroglobulinemia.
https://www.bocsci.com/pci-32765-ibrutinib-cas-936563-96-1-item-314184.html
View Contact Detail